Mankind Pharma Key Ratios
NSE: MANKIND | BSE: 543904
₹2,626.60
As on 16-Nov-2026IST
Market cap
₹1,08,424 Cr
Revenue (TTM)
₹15,379 Cr
P/E Ratio
48.3
P/B Ratio
6.2
Div. Yield
0 %
Key Ratios and Highlights
| Growth Score (%) | Quarterly | Annual (TTM) | |||
|---|---|---|---|---|---|
| Particulars | QoQ | YoY | 1-Year | 3-Years | 5-Years |
| Revenue | 7.62 | 17.33 | 13.53 | 17.71 | 18.10 |
| EBIT | 12.65 | 33.74 | 31.59 | 19.92 | 12.33 |
| Net Profit | 25.25 | 39.09 | 34.30 | 14.67 | 8.43 |
| EPS | 25.25 | 39.03 | 28.02 | 11.79 | 7.97 |
| Book Value | -- | -- | 13.69 | 28.49 | 27.28 |
| Key Ratios (%) | Average | Annual (TTM) | |||
|---|---|---|---|---|---|
| Particulars | 3-Years | 5-Years | TTM | Mar-26 | Mar-25 |
| EBIT-Margin
| 23.08 | 20.22 | 20.61 | 19.16 | 19.65 |
| Net Margin
| 18.71 | 16.07 | 14.32 | 13.24 | 15.75 |
| Return on equity
| 16.00 | 19.76 | 13.86 | 12.69 | 16.98 |
| Return on Capital
| 18.21 | 23.47 | -- | 13.24 | 18.32 |
| Return on Assets
| 11.63 | 13.58 | 7.79 | 7.00 | 10.15 |
| Debt to Equity (x)
| -- | -- | 0.17 | 0.37 | 0.58 |
Profitability
ROCE
--
--
Earning before interest and taxes / (Average net worth + Average total Debt) * 100
|
Company Name
|
TTM
|
Mar-26
|
Mar-25
|
Mar-24
|
Mar-23
|
|---|---|---|---|---|---|
|
Mankind Pharma
|
--
|
13.24
|
18.32
|
28.35
|
23.49
|
|
Peer Median
|
--
|
21.28
|
21.76
|
21.89
|
--
|
ROE
13.86
Lower than Peers by 1.06
Profit after tax / Average Net worth * 100
|
Company Name
|
TTM
|
Mar-26
|
Mar-25
|
Mar-24
|
Mar-23
|
|---|---|---|---|---|---|
|
Mankind Pharma
|
13.86
|
12.69
|
16.98
|
23.14
|
19.27
|
|
Peer Median
|
14.92
|
18.29
|
17.93
|
16.42
|
--
|
ROA
7.79
Lower than Peers by 2.07
Profit after tax / Average Total assets * 100
|
Company Name
|
TTM
|
Mar-26
|
Mar-25
|
Mar-24
|
Mar-23
|
|---|---|---|---|---|---|
|
Mankind Pharma
|
7.79
|
7.00
|
10.15
|
18.00
|
13.94
|
|
Peer Median
|
9.85
|
9.88
|
12.81
|
12.32
|
--
|
EBIT Margin
20.61
Higher than Peers by 2.93
Operating profit (EBIT) / Net Sales * 100
|
Company Name
|
TTM
|
Mar-26
|
Mar-25
|
Mar-24
|
Mar-23
|
|---|---|---|---|---|---|
|
Mankind Pharma
|
20.61
|
19.16
|
19.65
|
20.83
|
18.01
|
|
Peer Median
|
17.68
|
18.36
|
18.93
|
21.05
|
--
|
Net Margin
14.32
Higher than Peers by 0.55
Net profit / Total Income (Net sales plus other income) * 100
|
Company Name
|
TTM
|
Mar-26
|
Mar-25
|
Mar-24
|
Mar-23
|
|---|---|---|---|---|---|
|
Mankind Pharma
|
14.32
|
13.24
|
15.75
|
18.41
|
14.75
|
|
Peer Median
|
13.77
|
13.31
|
14.94
|
15.51
|
--
|
Cash Profit Margin
--
--
(Net profit + Depreciation) / Gross Sales * 100
|
Company Name
|
TTM
|
Mar-26
|
Mar-25
|
Mar-24
|
Mar-23
|
|---|---|---|---|---|---|
|
Mankind Pharma
|
--
|
18.91
|
20.73
|
21.72
|
17.96
|
|
Peer Median
|
--
|
--
|
--
|
--
|
--
|
Revenue Growth
13.53
Higher than Peers by 0.88
Year on year growth in net sales
|
Company Name
|
TTM
|
Mar-26
|
Mar-25
|
Mar-24
|
Mar-23
|
|---|---|---|---|---|---|
|
Mankind Pharma
|
13.53
|
16.96
|
18.98
|
17.27
|
12.44
|
|
Peer Median
|
12.65
|
16.05
|
10.90
|
13.44
|
--
|
EBIT Growth
31.59
Higher than Peers by 8.20
Year on year growth in operating profit (EBIT)
|
Company Name
|
TTM
|
Mar-26
|
Mar-25
|
Mar-24
|
Mar-23
|
|---|---|---|---|---|---|
|
Mankind Pharma
|
31.59
|
14.04
|
12.29
|
35.58
|
-13.59
|
|
Peer Median
|
23.39
|
20.72
|
15.01
|
23.50
|
--
|
Net Profit Growth
34.30
Higher than Peers by 11.52
Year on year growth in profit after tax
|
Company Name
|
TTM
|
Mar-26
|
Mar-25
|
Mar-24
|
Mar-23
|
|---|---|---|---|---|---|
|
Mankind Pharma
|
34.30
|
-3.41
|
3.39
|
48.19
|
-9.86
|
|
Peer Median
|
22.78
|
20.10
|
14.80
|
30.12
|
--
|
EPS Growth
28.02
Higher than Peers by 6.62
Year on year growth in earnings per share
|
Company Name
|
TTM
|
Mar-26
|
Mar-25
|
Mar-24
|
Mar-23
|
|---|---|---|---|---|---|
|
Mankind Pharma
|
28.02
|
-3.97
|
1.05
|
49.22
|
-10.58
|
|
Peer Median
|
21.40
|
19.29
|
14.27
|
29.02
|
--
|
Book Value Growth
--
--
Year on year growth in book value per share
|
Company Name
|
TTM
|
Mar-26
|
Mar-25
|
Mar-24
|
Mar-23
|
|---|---|---|---|---|---|
|
Mankind Pharma
|
--
|
13.74
|
52.99
|
25.62
|
20.79
|
|
Peer Median
|
--
|
--
|
--
|
--
|
--
|
Solvency
Debt to Equity
0.17
Higher than Peers by 0.17
Total debt / Net worth
|
Company Name
|
TTM
|
Mar-26
|
Mar-25
|
Mar-24
|
Mar-23
|
|---|---|---|---|---|---|
|
Mankind Pharma
|
0.17
|
0.37
|
0.58
|
0.02
|
0.02
|
|
Peer Median
|
0.00
|
0.05
|
0.06
|
0.03
|
--
|
Short term debt to equity ratio
--
--
(Short term borrowings / Net worth)
|
Company Name
|
TTM
|
Mar-26
|
Mar-25
|
Mar-24
|
Mar-23
|
|---|---|---|---|---|---|
|
Mankind Pharma
|
--
|
0.04
|
0.18
|
0.02
|
0.02
|
|
Peer Median
|
--
|
--
|
--
|
--
|
--
|
Current Ratio
1.35
Lower than Peers by 0.67
Current Assets / Current Liabilities and Provisions
|
Company Name
|
TTM
|
Mar-26
|
Mar-25
|
Mar-24
|
Mar-23
|
|---|---|---|---|---|---|
|
Mankind Pharma
|
1.35
|
1.07
|
1.23
|
3.10
|
2.32
|
|
Peer Median
|
2.03
|
1.90
|
1.90
|
2.23
|
--
|
Quick Ratio
0.95
Lower than Peers by 0.58
(Current Assets - Inventory) / Current Liabilities and Provisions
|
Company Name
|
TTM
|
Mar-26
|
Mar-25
|
Mar-24
|
Mar-23
|
|---|---|---|---|---|---|
|
Mankind Pharma
|
0.95
|
0.74
|
0.86
|
2.36
|
1.52
|
|
Peer Median
|
1.54
|
1.40
|
1.46
|
1.59
|
--
|
Interest Coverage
6.55
Lower than Peers by 15.21
Earning before interest and taxes (EBIT) / Interest Expenses
|
Company Name
|
TTM
|
Mar-26
|
Mar-25
|
Mar-24
|
Mar-23
|
|---|---|---|---|---|---|
|
Mankind Pharma
|
6.55
|
4.62
|
6.83
|
71.03
|
37.52
|
|
Peer Median
|
21.76
|
19.02
|
24.96
|
45.29
|
--
|
Operating Efficiency
Debtors to sales
14.17
Lower than Peers by 7.08
Debtors outstanding / Net Sales * 100
|
Company Name
|
TTM
|
Mar-26
|
Mar-25
|
Mar-24
|
Mar-23
|
|---|---|---|---|---|---|
|
Mankind Pharma
|
14.17
|
12.11
|
12.60
|
8.27
|
6.59
|
|
Peer Median
|
21.25
|
20.44
|
21.77
|
20.10
|
--
|
Asset Turnover
0.53
Lower than Peers by 0.19
Sales / Average Total Assets
|
Company Name
|
TTM
|
Mar-26
|
Mar-25
|
Mar-24
|
Mar-23
|
|---|---|---|---|---|---|
|
Mankind Pharma
|
0.53
|
0.54
|
0.64
|
0.99
|
0.97
|
|
Peer Median
|
0.72
|
0.74
|
0.76
|
0.81
|
--
|
Receivable days
--
--
Average Debtors / Sales * 365
|
Company Name
|
TTM
|
Mar-26
|
Mar-25
|
Mar-24
|
Mar-23
|
|---|---|---|---|---|---|
|
Mankind Pharma
|
--
|
39.93
|
34.35
|
24.35
|
19.33
|
|
Peer Median
|
--
|
--
|
--
|
--
|
--
|
Inventory Days
--
--
Average Inventory / Sales * 365
|
Company Name
|
TTM
|
Mar-26
|
Mar-25
|
Mar-24
|
Mar-23
|
|---|---|---|---|---|---|
|
Mankind Pharma
|
--
|
51.78
|
52.50
|
52.16
|
65.31
|
|
Peer Median
|
--
|
--
|
--
|
--
|
--
|
Payable days
--
--
Average Creditors / Cost of goods sold * 365
|
Company Name
|
TTM
|
Mar-26
|
Mar-25
|
Mar-24
|
Mar-23
|
|---|---|---|---|---|---|
|
Mankind Pharma
|
--
|
111.46
|
99.93
|
101.86
|
130.57
|
|
Peer Median
|
--
|
--
|
--
|
--
|
--
|
Cash Conversion Cycle
--
--
Receivable Days + Inventory Days - Payable Days
|
Company Name
|
TTM
|
Mar-26
|
Mar-25
|
Mar-24
|
Mar-23
|
|---|---|---|---|---|---|
|
Mankind Pharma
|
--
|
-19.75
|
-13.08
|
-25.35
|
-45.92
|
|
Peer Median
|
--
|
--
|
--
|
--
|
--
|
Valuation
Price / Earnings
48.35
Higher than Peers by 15.11
Current share price divided by earning per share in the last twelve months
|
Company Name
|
TTM
|
Mar-26
|
Mar-25
|
Mar-24
|
Mar-23
|
|---|---|---|---|---|---|
|
Mankind Pharma
|
48.35
|
43.29
|
50.22
|
48.11
|
--
|
|
Peer Median
|
33.23
|
33.23
|
26.81
|
39.85
|
--
|
Price / Book Value
6.17
Higher than Peers by 1.90
Current share price divided by book value per share in the latest financial year
|
Company Name
|
TTM
|
Mar-26
|
Mar-25
|
Mar-24
|
Mar-23
|
|---|---|---|---|---|---|
|
Mankind Pharma
|
6.17
|
5.09
|
7.00
|
9.85
|
--
|
|
Peer Median
|
4.26
|
4.44
|
4.65
|
6.11
|
--
|
Dividend Yield
0.04
Lower than Peers by 0.40
Dividend per share in the past twelve months divided by current share price
|
Company Name
|
TTM
|
Mar-26
|
Mar-25
|
Mar-24
|
Mar-23
|
|---|---|---|---|---|---|
|
Mankind Pharma
|
0.04
|
0.05
|
--
|
--
|
--
|
|
Peer Median
|
0.44
|
0.47
|
0.61
|
0.37
|
--
|
EV/EBITDA
25.56
--
Enterprise Value (Current Market Capitalisation + Total Debt - Cash & Equivalents) / Earnings before interest, taxes, depreciation and taxes (EBITDA)
|
Company Name
|
TTM
|
Mar-26
|
Mar-25
|
Mar-24
|
Mar-23
|
|---|---|---|---|---|---|
|
Mankind Pharma
|
25.56
|
22.19
|
30.28
|
32.74
|
-0.12
|
|
Peer Median
|
--
|
24.90
|
27.02
|
34.57
|
--
|
Market Cap
1,08,424
Higher than Peers by 90,604
Current Share price multiplied by latest total number of shares outstanding
|
Company Name
|
TTM
|
Mar-26
|
Mar-25
|
Mar-24
|
Mar-23
|
|---|---|---|---|---|---|
|
Mankind Pharma
|
1,08,424
|
82,802
|
99,979
|
92,032
|
--
|
|
Peer Median
|
17,821
|
17,451
|
20,914
|
25,297
|
--
|